VALN

VALN

Valneva SE ADR

Net โ€”top 1%Rev โ€”top 1%5Y
Hold

Valneva SE develops, manufactures, and commercializes prophylactic vaccines targeting infectious diseases. Its products include vaccines for Japanese encephalitis, cholera, chikungunya, Lyme disease, Zika virus, and more, serving markets in Europe and beyond.

โš•๏ธ Healthcare NASDAQ Listed 2021 โ‚ฌ EUR
$1,000 invested 5 years ago โ†’$216today

Score Overview

1 Year
Score
Net Growth-7x
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth3.00%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Scoreโ€”
Net Growthโ€”
Net Trendโ€”
Net Income Consistencyโ€”
Rev Growthโ€”
Rev Trendโ€”
Revenue Consistencyโ€”
All Time
Score
Net Growth-56.88%
Net Trend50%
Net Income Consistency
Rev Growth-49.82%
Rev Trend75%
Revenue Consistency

See the full market ranking โ†’

Valneva SE ADR fundamental performance

Across Valneva SE ADR's full reported history, from 2021 to 2025, revenue declined from โ‚ฌ 348M to โ‚ฌ 174M and net income went from -โ‚ฌ 73M to -โ‚ฌ 115M. Revenue increased in 75% of the years measured; net income in 50%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 5.55โ€”
1 Year2025-08-12
$ 9.40-40.96%
5 Years2021-08-12
$ 25.75-78.45%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2025โ‚ฌ 174M-โ‚ฌ 115Mโ‚ฌ 109M
2024โ‚ฌ 169M-โ‚ฌ 12Mโ‚ฌ 168M
2023โ‚ฌ 153M-โ‚ฌ 101Mโ‚ฌ 126M
2022โ‚ฌ 361M-โ‚ฌ 143Mโ‚ฌ 289M
IPO2021โ‚ฌ 348M-โ‚ฌ 73Mโ‚ฌ 346M

Explore beyond VALN

You're looking at Valneva SE ADR. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies